Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday.

According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

Several other analysts have also weighed in on ENTA. JMP Securities upgraded Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 price target on the stock in a report on Tuesday, July 11th. BidaskClub lowered Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Robert W. Baird increased their target price on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 8th. J P Morgan Chase & Co reiterated an “overweight” rating and issued a $38.00 target price (up previously from $32.00) on shares of Enanta Pharmaceuticals in a research note on Wednesday, August 9th. Finally, Royal Bank Of Canada started coverage on Enanta Pharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Enanta Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $42.33.

Enanta Pharmaceuticals (ENTA) traded up 1.35% during mid-day trading on Wednesday, reaching $48.13. 133,326 shares of the company traded hands. The company’s 50 day moving average price is $42.82 and its 200 day moving average price is $35.85. Enanta Pharmaceuticals has a 12-month low of $22.17 and a 12-month high of $48.20. The firm’s market capitalization is $918.80 million.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative return on equity of 7.74% and a negative net margin of 51.85%. The company had revenue of $7.51 million for the quarter, compared to analyst estimates of $8.08 million. During the same quarter in the prior year, the firm posted ($0.06) EPS. Enanta Pharmaceuticals’s quarterly revenue was down 46.3% compared to the same quarter last year. Equities research analysts predict that Enanta Pharmaceuticals will post $1.14 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/04/enanta-pharmaceuticals-inc-enta-stock-rating-lowered-by-zacks-investment-research.html.

A number of hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. grew its position in shares of Enanta Pharmaceuticals by 43.0% during the 2nd quarter. Goldman Sachs Group Inc. now owns 83,704 shares of the biotechnology company’s stock worth $3,012,000 after buying an additional 25,154 shares in the last quarter. Krensavage Asset Management LLC grew its position in shares of Enanta Pharmaceuticals by 0.6% during the 2nd quarter. Krensavage Asset Management LLC now owns 1,104,992 shares of the biotechnology company’s stock worth $39,758,000 after buying an additional 6,468 shares in the last quarter. Stonepine Capital Management LLC grew its position in shares of Enanta Pharmaceuticals by 165.9% during the 2nd quarter. Stonepine Capital Management LLC now owns 492,265 shares of the biotechnology company’s stock worth $17,712,000 after buying an additional 307,166 shares in the last quarter. Voya Investment Management LLC grew its position in shares of Enanta Pharmaceuticals by 13.3% during the 2nd quarter. Voya Investment Management LLC now owns 8,350 shares of the biotechnology company’s stock worth $300,000 after buying an additional 977 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Enanta Pharmaceuticals by 34.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 554,777 shares of the biotechnology company’s stock worth $19,961,000 after buying an additional 141,688 shares in the last quarter. Institutional investors and hedge funds own 66.07% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.